DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/rf3clh/20152019_europe) has announced the addition of the "2015-2019 Europe Flow Cytometry Market: Emerging Opportunities for Instrument and Reagent Suppliers--Competitive Strategies, Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Instrumentation Review" report to their offering.
This unique report contains 270 pages, 75 tables and provides information not available from any other published source, including test volume forecasts, instrument placements and installed base by manufacturer and model, as well as sales and market shares of leading instrument and reagents suppliers.
This 5-country report will help current suppliers and potential market entrants identify and evaluate emerging opportunities in the flow cytometry markets during the next five years. The report explores future marketing and technological trends in five major European countries (France, Germany, Italy, Spain, and the UK); provides market share estimates, test volume forecasts, and instrument placements; compares features of major clinical and research flow cytometers; profiles competitors and emerging market entrants; and suggests specific product and marketing opportunities for flow cytometry instruments and reagents.
During the next five years, continued advances in molecular diagnostics, monoclonal antibodies, lasers and IT, as well as growing understanding of immunologic forces regulating systemic diseases, will have a profound impact on the flow cytometry markets worldwide. New molecular diagnostic and monoclonal antibody tests will facilitate existing procedures and provide basis for sensitive, specific and simple assays. The introduction of smaller and easy-to-operate laser systems will further expand applications of flow cytometry to routine clinical laboratories. Further advances in IT will reduce the cost of instrument manufacture, service warranty, and permit development of self-troubleshooting, autocalibration and other advanced features. Presently tedious analyses of chromosomal abnormalities, DNA content, and lymphocyte subsets will become more automated and routine.
For more information visit http://www.researchandmarkets.com/research/rf3clh/20152019_europe